All In Biotech

Drug Trial Radar · NCT03370536

ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization

Panoramic ECGi to Guide Ablation of Non-Paroxysmal AF: Effect of Ibutilide on AF Source Location and Organization

Last checked: Nov 19, 2026Latest source record: Feb 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

1

Actual

Start

Nov 1, 2017

Primary completion

Jul 18, 2018

Study completion Jul 18, 2018

Sponsor

Lead sponsor
Vivek ReddyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medtronic
First posted
Dec 12, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, non-randomized, un-blinded, observational trial.

Conditions

  • Atrial Fibrillation
  • Persistent Atrial Fibrillation

Interventions

  • CardioInsight ECGI Mapping SystemDevice

    The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.

  • AF ablationProcedure

    Empiric ablation (CFAE or linear ablation) is not permitted

  • IbutilideDrug

    Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who no Longer Has Recurrent At/AFTime frame: at 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Icahn School of Medicine at Mount Sinai

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.